BCL2 and neoplasm: BCL-2 also shows promise in clinical outcomes of CAR-T treatment [210] and resistance to small molecules promoting tumor apoptosis, undergoing intense preclinical and clinical research in hematologic malignancies, mimicking the action of the BH3-only proteins, including venetoclax [211].